{
    "nct_id": "NCT01421056",
    "title": "A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment",
    "status": "COMPLETED",
    "last_update_time": "2014-01-07",
    "description_brief": "The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "CHF 5074 (aka CSP-1103) \u2014 small-molecule \u03b3-secretase modulator and microglial modulator; NSAID-derived, non\u2011COX inhibitor."
    ],
    "placebo": [
        "Matching placebo (randomized, placebo-controlled design reported)."
    ],
    "explanation_target": [
        "Reason: The trial tests CHF 5074 in patients with mild cognitive impairment (MCI). CHF 5074 has been described in preclinical and clinical reports as a small-molecule \u03b3-secretase modulator that reduces brain A\u03b2 pathology and also acts as a microglial/neuroinflammation modulator \u2014 i.e., it targets Alzheimer\u2019s-related pathology rather than being a symptomatic cognitive enhancer or a biologic. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Act: Key trial details from the description \u2014 randomized, placebo-controlled, ascending oral doses of CHF 5074 (200, 400, 600 mg/day) for up to 12 weeks in MCI patients \u2014 are consistent with the Phase 2 study report. Clinical and biomarker endpoints included safety/tolerability and exploration of markers of clinical efficacy; the published Phase 2 report showed dose-dependent CNS effects on inflammatory biomarkers (e.g., CSF sCD40L, TNF\u2011\u03b1) though cognitive benefits were limited/trend-level in subgroups. \ue200cite\ue202turn0search6\ue202turn0search0\ue201",
        "Drug identity / supporting web findings: CHF 5074 is also referenced as CSP-1103 and described across multiple sources as a small-molecule \u03b3-secretase modulator that reduced A\u03b2 plaque burden and improved memory in AD mouse models, and as a microglial/neuroinflammation modulator in human MCI studies. It is an NSAID derivative that lacks COX inhibitory activity per pharmacology reports. \ue200cite\ue202turn0search3\ue202turn0search2\ue202turn0search4\ue201",
        "Classification decision: Because CHF 5074 is a small molecule that modulates \u03b3-secretase/A\u03b2 production and neuroinflammation \u2014 mechanisms aimed at altering disease biology \u2014 the correct category is 'disease-targeted small molecule' rather than a biologic, pure cognitive enhancer, or neuropsychiatric symptom treatment. (The literature sometimes emphasizes its microglial-modulating/anti\u2011inflammatory effects, but these are pharmacologic effects of a small molecule directed at AD pathology.) \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect / caveats: Some sources label CHF 5074 as a 'microglial modulator' (neuroinflammation focus) while others emphasize \u03b3-secretase modulation and A\u03b2 effects; both are disease-modifying mechanisms and consistent with a small-molecule, pathology-targeting agent. The trial you provided is a safety/tolerability Phase 2 MCI study (with placebo control) exploring biomarker signals rather than a symptomatic-only cognitive\u2011enhancer study. If you want, I can fetch the full Phase 2 paper or clinicaltrials.gov entry for direct protocol text. \ue200cite\ue202turn0search0\ue202turn0search6\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The investigational drug CHF 5074 (CSP-1103) is described in the literature as a small-molecule \u03b3\u2011secretase modulator that lowers A\u03b2 production/brain A\u03b2 pathology AND as a microglial / neuroinflammation modulator (reducing CSF TNF-\u03b1, sCD40L and shifting microglial phenotype). Both amyloid-related and inflammatory mechanisms are explicitly reported for this molecule, so the trial is targeting more than one CADRO category. \ue200cite\ue202turn2search0\ue202turn1search0\ue202turn1search2\ue201",
        "Act: Extracted details from the trial description and publications: CHF 5074 / CSP-1103 is an NSAID-derived, non-COX inhibitor small molecule that acts as a \u03b3\u2011secretase modulator and has been shown in transgenic mouse studies to reduce brain A\u03b2/plaque burden and improve cognition. \ue200cite\ue202turn2search0\ue202turn2search1\ue201 The Phase\u20112 randomized, placebo\u2011controlled 12\u2011week MCI study (200/400/600 mg/day) reported dose-dependent CNS effects on inflammatory CSF biomarkers (sCD40L, TNF\u2011\u03b1) and measurable CSF drug levels, with limited cognitive effects overall. \ue200cite\ue202turn1search0\ue201 Preclinical and ex vivo work also documents CHF5074\u2019s effects on microglial polarization and suppression of A\u03b2\u2011induced pro-inflammatory cytokines, consistent with a direct microglial/neuroinflammation-modulatory action. \ue200cite\ue202turn1search2\ue201",
        "Reflect: CADRO mappings \u2014 A) Amyloid beta covers interventions that alter A\u03b2 production/aggregation; F) Inflammation covers microglial/neuroinflammatory modulation. Because CHF 5074 has experimentally supported activity on both A\u03b2 (via \u03b3\u2011secretase modulation and reduced plaque burden) and on neuroinflammation/microglia (reduced CSF TNF\u2011\u03b1 and sCD40L, M2\u2011shift in microglia), the most accurate CADRO classification is R) Multi-target (covers interventions with two distinct disease\u2011related mechanisms). I reviewed whether one mechanism dominates: while some reports emphasize its microglial effects, there is strong preclinical evidence of direct A\u03b2\u2011lowering through \u03b3\u2011secretase modulation, so assigning a single category (A or F) would omit an important, supported mechanism. \ue200cite\ue202turn2search0\ue202turn1search0\ue202turn1search2\ue201",
        "Output: R) Multi-target \u2014 CHF 5074 (CSP\u20111103) targets both amyloid-related biology (\u03b3\u2011secretase modulation / reduced A\u03b2) and neuroinflammation/microglial pathways, so the trial fits CADRO category R) Multi-target."
    ]
}